Full-Time
Power Apps Engineer
Updated on 8/23/2026
Stryker
10,001+ employees
Manufactures orthopedic and surgical medical devices
No salary listed
Gurugram, Haryana, India
Hybrid
Hybrid work arrangement with 10% travel.
 Software Engineering (1) |
|---|
Get referred to Stryker
See people who can refer or advise you
- At least 3 years of experience developing applications in Microsoft Power Apps.
- Strong hands-on experience with Canvas Apps.
- Proficiency in Power Fx formulas and application performance optimization.
- Experience integrating applications with REST APIs and external systems.
- Knowledge of relational data modeling and experience working with Microsoft Dataverse.
- Experience with role-based security and environment management.
- Ability to work independently and in cross-functional teams.
- Design, develop, test, and maintain Canvas Apps within Microsoft Power Platform.
- Build responsive user interfaces using Power Fx formulas.
- Integrate applications with Microsoft Dataverse, SharePoint, Microsoft SQL Server, and other APIs.
- Implement automation workflows using Microsoft Power Automate.
- Ensure performance optimization, security, and governance best practices.
- Collaborate with business stakeholders to gather requirements and translate them into technical solutions.
- Troubleshoot, debug, and enhance existing applications.
- Support deployment processes and lifecycle management using solution management practices.
- Document technical designs, data flows, and support procedures.
- Experience with Model-Driven Apps within Microsoft Power Platform.
- Familiarity with Azure services such as Microsoft Azure.
- Understanding of DevOps practices and application lifecycle management strategies.
- Experience with continuous integration/continuous delivery pipelines and source control.
- Microsoft certifications such as PL-100 or PL-400.
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Get referred to Stryker
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 9.4% to $6.6 billion; organic growth reached 9.0%.
- Management narrowed 2026 guidance to 8.3%-9.3% organic growth and $14.95-$15.10 EPS.
- Defense Logistics Agency awarded Stryker a $100 million contract modification in 2026.
What critics are saying
- March 11, 2026 cyberattack disrupted ordering, shipping, and manufacturing, hitting Q1 and Q2.
- FDA recall Z-2865-2026 on June 8, 2026 exposed leaking handpiece complaints across 11,857 units.
- A March 2026 breach lawsuit threatens damages, discovery costs, and trust erosion for years.
What makes Stryker unique
- Mako robotics drove Q2 2026 organic growth; 2.5 million procedures validate workflow lock-in.
- Pangea Plating launched in Europe on May 27, 2026, widening trauma franchise depth.
- AVS acquisition on May 7, 2026 adds intravascular lithotripsy to peripheral vascular.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Stryker started 2026 with strong underlying demand despite a cyber disruption. The medical technology company reported 9% organic sales growth in the second quarter, with MedSurg & Neurotechnology rising 9.2% and Orthopaedics up 8.6%. International sales grew 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. Mako Robotics continues to drive growth, with more than 2.5 million procedures performed globally and systems installed across 47 countries. US knee sales increased 6.2% on continued Mako adoption. The company has a market capitalisation of $125.7 billion. Its bottom line is expected to improve 10.4% over the next five years. However, shares have fallen 6.7% this year, whilst the industry declined 15.2%.
Stryker's Michigan sales unit secured a $100 million contract modification from the US Defense Logistics Agency, reinforcing its position as a key government healthcare supplier. The award complements Stryker's hospital and surgical product revenue, adding government-backed visibility. The company maintains its steady dividend track record, with a quarterly $0.88 per-share payout affirmed in August 2026. However, investors face ongoing concerns including regulatory friction, supply chain pressure, and pricing strain from government payers. Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029, requiring 8.9% yearly revenue growth. Fair value estimates from the Simply Wall St Community range from $331 to $426 per share. The contract highlights stable government contracting but does not fundamentally alter Stryker's near-term catalysts or main investment risks.
Stryker shares fell 6.42% following its second-quarter 2026 earnings release, which showed sales of $6.59 billion and net income of $1.28 billion. The medical technology company is now trading approximately 23% below one valuation estimate and 18% beneath the average analyst target. Analysts currently place Stryker's fair value at $386.80, compared to its recent closing price of $325.70. Price targets vary significantly amongst analysts, ranging from $315 to $465. The year-to-date share price return has fallen 6.46%, though the company maintains a five-year total shareholder return of 30.66%. Potential risks to the company's outlook include prolonged EU regulatory delays and sustained supply chain disruptions that could affect product launches and margins.
Stryker reported Q2 revenue of $6.59 billion, up 9.4% year on year, meeting Wall Street expectations. The medical technology company's non-GAAP earnings of $3.69 per share beat analyst estimates by 5.8%. Despite meeting forecasts, investors reacted negatively due to supply chain disruptions in the peripheral vascular business. Chief executive Kevin Lobo said the quarter focused on recovery from a recent cybersecurity incident, which caused production disruptions and elevated backlogs. The company expects backorders to normalise by the end of Q3. Management cited strong demand for capital equipment and Mako robotics, which saw record Q2 installations. Operating margin expanded to 25.2% from 18.5% last year, supported by operational discipline and efficiency initiatives. Management slightly raised full-year adjusted earnings guidance.
Stryker reported strong second-quarter 2026 results with 9% organic sales growth, driven by high single-digit gains in both its med surg and neurotechnology and orthopaedics businesses. The medical device company is recovering from a cybersecurity incident whilst ramping up production to meet demand. In the US, Stryker achieved 9% organic sales growth, with double-digit expansion in its medical, trauma extremities, and endoscopy divisions. The company's OrthoTech and instruments segments posted high single-digit growth. However, supply disruptions affected the peripheral vascular business, creating a significant backorder situation and lost sales. Stryker expects to resolve these issues by the end of the third quarter. The company also completed its acquisition of AVS during the quarter and remains confident in the long-term outlook for its peripheral vascular business.